The purpose of this study is to determine if a single dose of IL-10 compared to placebo is safe and effective in reducing the incidence of post-ERCP acute pancreatitis for subjects with increased risk.

Inclusion criteria:

Adults weighing up to 125 kg who are undergoing ERCP for any of the following:

• Evaluate recurrent abdominal pain;
• Evaluate unexplained recurrent pancreatitis;
• Evaluate prior post-ERCP pancreatitis;
• Treatment of pancreatic disorders;
• Treatment of Common Bile Duct Stones (without jaundice)

Exclusion criteria:

• Active (acute) pancreatitis;
• Chronic pancreatitis (moderate and severe cases);
• ERCP to perform a second procedure on biliary tract;
• Patients who previously had pancreatic sphincterotomy;
• Known or suspected pancreatic cancer or cancer of Papilla of Vater;
• Known or suspected other malignancy;
• History of, or current clotting or bleeding problems;
• Moderate and severe Anemia;
• Low platelet counts